Page 10 - Precision Vaccines Program News Today

The Moderna and Pfizer/BioNTech Covid-19 vaccines are now authorized for emergency use in young children. The US Food and Drug Administration expanded the authorizations for the vaccines Friday to include

The Moderna and Pfizer/BioNTech Covid-19 vaccines are now authorized for emergency use in young children. The US Food and Drug Administration expanded the authorizations for the vaccines Friday to include

The Moderna and Pfizer/BioNTech Covid-19 vaccines are now authorized for emergency use in young children. The US Food and Drug Administration expanded the authorizations for the vaccines Friday to include

CBS 58 is your local source for the Milwaukee news, Milwaukee weather, and Milwaukee sports.

The Food and Drug Administration advisers have allowed the recommendation of both Moderna and Pfizer-BioNTech COVID-19 vaccine for children, which closes the final challenge to getting young Americans vaccinated.

On Wednesday, the same FDA advisory committee will discuss allowing COVID vaccines from Moderna and Pfizer for younger children.

To answer that question, expanded testing is needed that can determine levels of T immune cells

Researchers at the Precision Vaccines Program at Boston Children’s Hospital recently partnered with the Expanded Program on Immunization Consortium, an international team studying early life immunization, to collect and comprehensively profile blood samples from newborns immunized with the century-old Bacille Calmette-Guérin (BCG) vaccine, using a powerful “big data” approach.

The century-old Bacille Calmette-Guérin (BCG) vaccine against tuberculosis is one of the world's oldest and most widely used vaccines, used to immunize 100 million newborns every year. Given in countries with endemic TB, it has surprisingly been found to protect newborns and young infants against multiple bacterial and viral infections unrelated to TB. There's even some evidence that it can reduce severity of COVID-19.

This article is part of Harvard Medical School’s continuing coverage of COVID-19.